NCT06942910 - A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria | Biotech Hunter

Enrollment

224

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Chronic Kidney Disease With High Proteinuria

Interventions

DRUG

Zibotentan/Dapagliflozin

Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to

DRUG

Dapagliflozin

Participants will receive dapagliflozin in fixed-dose combination as per the arms they are randomized to

Trial Locations (10)

111539

RECRUITING

Research Site, Moscow

117036

RECRUITING

Research Site, Moscow

129327

RECRUITING

Research Site, Moscow

150062

RECRUITING

Research Site, Yaroslavl

195067

RECRUITING

Research Site, Saint Petersburg

410053

RECRUITING

Research Site, Saratov

410054

RECRUITING

Research Site, Saratov

426061

SUSPENDED

Research Site, Izhevsk

614000

RECRUITING

Research Site, Perm

624002

RECRUITING

Research Site, Aramil